BSI has a novel biotech platform for sustainable and improved production of consistent, high quality Advanced Botanical Materials (ABM). ABM-01 is the first ABM produced by the company, based on a plant which is native to Chile called Quillaja saponaria. ABM-01 enables a sustainable large scale production of the gold standard adjuvant QS-21, that boost the innate immune system response and ultimately improves the efficacy of modern vaccine candidates.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):